Treatment of Frontotemporal Dementia (original) (raw)
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Seltman R, Matthews B. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs. 2012;26:841–70. Excellent review article of FTLD syndromes. ArticlePubMedCAS Google Scholar
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain. 2011;134:2456–77. ArticlePubMedPubMed Central Google Scholar
Gorno-Tempini ML, HIllis A, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14. ArticlePubMedPubMed Central Google Scholar
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszeweski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1–9. ArticlePubMedCAS Google Scholar
Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23:394–400. ArticlePubMed Google Scholar
Brooks B, Miller R, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9. ArticlePubMedCAS Google Scholar
Ringholz G, Appel S, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586. ArticlePubMedCAS Google Scholar
Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1–4. ArticlePubMedPubMed Central Google Scholar
Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3:343. ArticlePubMed Google Scholar
Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:93107. Article Google Scholar
Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178–85. ArticlePubMedCAS Google Scholar
Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatr. 2007;15:84–7. Article Google Scholar
Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int. 2013;13:506–7. ArticlePubMed Google Scholar
Litvan I, Gomez C, Atack JR, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989;26(3):404–7. ArticlePubMedCAS Google Scholar
Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103(2):123–5. ArticlePubMedCAS Google Scholar
Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467–73. ArticlePubMedCAS Google Scholar
Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70–4. ArticlePubMedCAS Google Scholar
Diehl-Schmid J, Förstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatr. 2008;23:754–9. Article Google Scholar
Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21:164–6. ArticlePubMed Google Scholar
Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211–7. ArticlePubMedCASPubMed Central Google Scholar
Vercelletto M, Boutoleau-Bretonnière C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimer Dis. 2011;23:749–59. First large randomized, double-blind, controlled trial of memantine in FTD patients that did not reach primary endpoints. Google Scholar
Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149–56. Large multi-center, randomized, double-blind, controlled therapeutic trial demonstrating memantine lack of efficacy. ArticlePubMedCASPubMed Central Google Scholar
Hermann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatr. 2012;20:789–97. Article Google Scholar
Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212–6. ArticlePubMedCAS Google Scholar
Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742–5. ArticlePubMed Google Scholar
Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behavior in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler. 2007;8:189–90. ArticlePubMedCAS Google Scholar
Prodan CI, Monnon M, Ross ED. Behavioral abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry. 2009;80:1416–7. ArticlePubMedCAS Google Scholar
Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17:267–72. ArticlePubMed Google Scholar
Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavioral symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13–9. ArticlePubMedCAS Google Scholar
Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognitive in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharamcology (Berl). 2004;172:400–8. ArticleCAS Google Scholar
Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemoporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355–9. ArticlePubMedCAS Google Scholar
Curtis RC, Resch DS. Case of pick’s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000;20:384–5. ArticlePubMedCAS Google Scholar
Fellgiebel A, Müller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8:123–6. ArticlePubMed Google Scholar
Reeves RR, Perry CL. Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. J Clin Psychopharmacol. 2013;33:145–6. ArticlePubMed Google Scholar
Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205–14. ArticlePubMed Google Scholar
Huey ED, Garcia C, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2008;69:1981–2. ArticlePubMed Google Scholar
Pijnenburg YA, Sampson EL, Harvey RJ, et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatr. 2003;18:67–72. ArticleCAS Google Scholar
Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11: CD006625. doi:10.1002/14651858.CD006625.pub3. Meta-Analysis of side effect and efficacy profile of many antipsychotics. PubMed Google Scholar
Mioshi E, Foxe D, Leslie F, et al. The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:68–73. ArticlePubMed Google Scholar
Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17–22. ArticlePubMedCAS Google Scholar
Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651–8. ArticlePubMedCASPubMed Central Google Scholar
Poetter CE, Stewart JT. Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. J Clin Psychopharmacol. 2012;31:137–8. Article Google Scholar
Cruz M, Marinho V, Fontenelle LF, et al. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol. 2008;21:104–6. ArticlePubMed Google Scholar
Nestor PJ. Reversal of abnormal eating and drinking behavior in a frontotemporal lobar degeneration patient using low-dose topiramate. J Neurol Neurosurg Psychiatry. 2012;83:349–50. ArticlePubMed Google Scholar
Singam C, Walterfang M, Mocellin R, et al. Topiramate for abnormal eating behavior in frontotemporal dementia. Behav Neurol. 2013;27:285–6. ArticlePubMed Google Scholar
Shinagawa S, Tsuno N, Nakayama K. Managing abnormal eating behaviors in frontotemporal lobar degeneration in patients with topiramate. Psychogeriatrics. 2013;13:58–61. ArticlePubMed Google Scholar
Jesso S, Morlog D, Ross S, et al. The effects of oxytocin on social cognition and behavior in frontotemporal dementia. Brain. 2011;134:2493–501. ArticlePubMed Google Scholar
Sha SJ, Boxer A. Treatment implications of C9ORF72. Alzheiemers Res Ther. 2012;4:46. ArticleCAS Google Scholar
Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropatholgoical featuers of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2011;82:196–203. ArticlePubMedPubMed Central Google Scholar
DeJesus-Hernandez M, Mackenzie IR, et al. Expanded GGGC CC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.
Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–68. ArticlePubMedCASPubMed Central Google Scholar
Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91. ArticlePubMedCAS Google Scholar
Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31. ArticlePubMedCAS Google Scholar
Klawans Jr HL, Ringel SP. Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol. 1971;5(2):115–29. ArticlePubMed Google Scholar
Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998;55(8):1099–102. ArticlePubMedCAS Google Scholar
Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17(6):1255–64. ArticlePubMed Google Scholar
Kortte K, Rogalski E. Behavioural interventions for enhancing life participation in behavioral variant frontotemporal dementia and primary progressive aphasia. Int Rev Psychiatr. 2013;25:237–45. Review of non-pharmacological interventions for FTD patients. Article Google Scholar
Höglinger GU, Huppertz HJ, Wagenpfeil S, TAUROS MRI Investigators, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord. 2014;29(4):479–87. ArticlePubMed Google Scholar
Tolosa E, Litvan I, Höglinger GU, TAUROS Investigators, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–8. ArticlePubMedCAS Google Scholar
Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–14. ArticlePubMedCAS Google Scholar
Boxer A, Lang A, Grossman M, AL-108-231 investigators. Davunetide in patients with progressive supranuclear palsy: a randomized, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13:676–85. Largest clinical trial of PSP to date. ArticlePubMedCAS Google Scholar
Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415–28. ArticlePubMedCASPubMed Central Google Scholar
Su Z, Zhang Y, Gendron TF, et al. Discovery of a biomarker and lead small molecules to target r(GGGG CC)-associated defects in c9FTD/ALS. Neuron. 2014. doi:10.1016/j.neuron.2014.07.041.